November 13, 2018 / 6:49 AM / a month ago

BRIEF-Erytech Pharma 9-Month Operating Loss Widens To 34.1 Million Euros

Nov 13 (Reuters) - ERYTECH PHARMA SA:

* ANNOUNCED ON MONDAY CASH POSITION OF EUR 146.9 MLN AS OF SEPT 30, 2018, COMPARED WITH EUR 185.5 MLN AS OF DEC 31, 2017

* 9-MONTH NET LOSS EUR 30.2 MLN, COMPARED TO LOSS OF EUR 20.8 MLN IN THE SAME PERIOD OF 2017

* 9-MONTH OPERATING LOSS EUR 34.1 MLN VS LOSS OF EUR 21.1 MLN YEAR AGO

* 9-MONTH TOTAL OPERATING INCOME EUR 2.6 MLN VS EUR 2.9 MLN YEAR AGO

* PHASE 2 TRIAL IN TRIPLE-NEGATIVE BREAST CANCER TO ENROLL PATIENTS BY YEAR END

* PHASE 3 TRIAL FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER ENROLLING PATIENTS

Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below